Accepted for/Published in: JMIR Research Protocols
Date Submitted: May 28, 2024
Date Accepted: Jul 11, 2024
Effect of Semaglutide on Body Composition, Physical Function, and Biomarkers of Aging in Older, Overweight Adults with Insulin Resistance: Protocol for an Open-labeled Randomized Controlled Trial
ABSTRACT
Background:
Older adults with type 2 diabetes mellitus (T2DM) or prediabetes are at increased risk of adverse changes in body composition, physical function, and concentrations of biomarkers of aging compared with those with normal glucose tolerance. Semaglutide is a glucagon-like peptide 1 receptor agonist that has been approved for T2DM and chronic weight management. Although semaglutide is effective for weight loss and T2DM management, its effects on lean body mass, physical function, and biomarkers of aging are understudied in older adults.
Objective:
This randomized, open-label, controlled trial aims to compare the effects of semaglutide in addition to lifestyle counseling vs. lifestyle counseling alone on body composition, physical function, and biomarkers of aging in 20 older adults (n=10 per group) with elevated BMI (27-40 kg/m2) and glucose intolerance (HgbA1c 5.7-7.5%).
Methods:
Older adults (≥65 y) with prediabetes or well-controlled T2DM will be recruited, stratified by gender, and randomized to one of the two groups (semaglutide plus lifestyle counseling vs lifestyle counseling alone) and followed for five months. Those in the semaglutide group will be titrated to 1 mg weekly, as tolerated, for 12 weeks. Lifestyle counseling will be given by Registered Dietitians and is based on the Diabetes Prevention Program Lifestyle Change Program. Our primary outcomes include changes in lean mass, physical function, and biomarkers of aging. Body composition will be measured by dual-energy X-ray absorptiometry and include total fat mass and lean mass. Physical function will be measured by 6-minute walk distance, grip strength, and short physical performance battery. Biomarkers of aging will be measured in blood, skeletal muscle, and abdominal adipose tissue to include C-reactive protein, interleukin-6, tumor necrosis factors α, and β galactosidase staining.
Results:
The study was funded in December 2021 with a projected data collection period from April 2023 through Summer 2024.
Conclusions:
Despite the elevated risk of adverse changes in body composition, physical function, and biomarkers of aging among older adults with glucose intolerance and elevated adiposity, the benefits, and risks of commonly prescribed anti-hyperglycemic or weight loss medications such as semaglutide are understudied. This study aims to fill this knowledge gap to inform clinicians about non-glycemic effects of semaglutide and optimize management in this population.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.